OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O6-methylguanine DNA methyltransferase as a biomarker for response
Dwight H. Owen, Andrew J. Alexander, Bhavana Konda, et al.
Oncotarget (2017) Vol. 8, Iss. 61, pp. 104046-104056
Open Access | Times Cited: 41
Dwight H. Owen, Andrew J. Alexander, Bhavana Konda, et al.
Oncotarget (2017) Vol. 8, Iss. 61, pp. 104046-104056
Open Access | Times Cited: 41
Showing 1-25 of 41 citing articles:
Glioblastoma under Siege: An Overview of Current Therapeutic Strategies
Mayra Paolillo, Cinzia Boselli, Sergio Schinelli
Brain Sciences (2018) Vol. 8, Iss. 1, pp. 15-15
Open Access | Times Cited: 121
Mayra Paolillo, Cinzia Boselli, Sergio Schinelli
Brain Sciences (2018) Vol. 8, Iss. 1, pp. 15-15
Open Access | Times Cited: 121
177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors
Satya Das, Taymeyah Al‐Toubah, Ghassan El‐Haddad, et al.
Expert Review of Gastroenterology & Hepatology (2019) Vol. 13, Iss. 11, pp. 1023-1031
Open Access | Times Cited: 92
Satya Das, Taymeyah Al‐Toubah, Ghassan El‐Haddad, et al.
Expert Review of Gastroenterology & Hepatology (2019) Vol. 13, Iss. 11, pp. 1023-1031
Open Access | Times Cited: 92
Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023
Gianpaolo di Santo, Giulia Santo, Anna Sviridenko, et al.
Theranostics (2024) Vol. 14, Iss. 3, pp. 940-953
Open Access | Times Cited: 14
Gianpaolo di Santo, Giulia Santo, Anna Sviridenko, et al.
Theranostics (2024) Vol. 14, Iss. 3, pp. 940-953
Open Access | Times Cited: 14
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms
Jennifer R. Eads, Þorvarður R. Hálfdánarson, Tim Asmis, et al.
Endocrine Related Cancer (2023) Vol. 30, Iss. 8
Open Access | Times Cited: 19
Jennifer R. Eads, Þorvarður R. Hálfdánarson, Tim Asmis, et al.
Endocrine Related Cancer (2023) Vol. 30, Iss. 8
Open Access | Times Cited: 19
An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors
Omalkhaire M. Alshaikh, L. Sylvia, Özgür Mete, et al.
Endocrine Pathology (2019) Vol. 30, Iss. 2, pp. 118-127
Closed Access | Times Cited: 53
Omalkhaire M. Alshaikh, L. Sylvia, Özgür Mete, et al.
Endocrine Pathology (2019) Vol. 30, Iss. 2, pp. 118-127
Closed Access | Times Cited: 53
Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor
Louis de Mestier, Thomas Walter, Camille Evrard, et al.
Neuroendocrinology (2019) Vol. 110, Iss. 1-2, pp. 83-91
Open Access | Times Cited: 49
Louis de Mestier, Thomas Walter, Camille Evrard, et al.
Neuroendocrinology (2019) Vol. 110, Iss. 1-2, pp. 83-91
Open Access | Times Cited: 49
Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs)
Katharine Thomas, Brianne A. Voros, Meghan M. Taylor, et al.
Cancers (2020) Vol. 12, Iss. 1, pp. 206-206
Open Access | Times Cited: 47
Katharine Thomas, Brianne A. Voros, Meghan M. Taylor, et al.
Cancers (2020) Vol. 12, Iss. 1, pp. 206-206
Open Access | Times Cited: 47
Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses
Louis de Mestier, Thomas Walter, Hédia Brixi, et al.
Neuroendocrinology (2019) Vol. 108, Iss. 4, pp. 343-353
Closed Access | Times Cited: 44
Louis de Mestier, Thomas Walter, Hédia Brixi, et al.
Neuroendocrinology (2019) Vol. 108, Iss. 4, pp. 343-353
Closed Access | Times Cited: 44
Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma — retrospective analysis
Wojciech Rogowski, Ewa Wachuła, Anita Gorzelak-Magiera, et al.
Endokrynologia Polska (2019) Vol. 70, Iss. 4, pp. 313-317
Open Access | Times Cited: 44
Wojciech Rogowski, Ewa Wachuła, Anita Gorzelak-Magiera, et al.
Endokrynologia Polska (2019) Vol. 70, Iss. 4, pp. 313-317
Open Access | Times Cited: 44
Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors
Malcolm H. Squires, Patrick J. Worth, Bhavana Konda, et al.
Pancreas (2020) Vol. 49, Iss. 3, pp. 355-360
Closed Access | Times Cited: 42
Malcolm H. Squires, Patrick J. Worth, Bhavana Konda, et al.
Pancreas (2020) Vol. 49, Iss. 3, pp. 355-360
Closed Access | Times Cited: 42
Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms
Taymeyah Al‐Toubah, Eleonora Pellè, Tiffany Valone, et al.
Journal of the National Comprehensive Cancer Network (2021) Vol. 20, Iss. 1, pp. 29-36
Open Access | Times Cited: 36
Taymeyah Al‐Toubah, Eleonora Pellè, Tiffany Valone, et al.
Journal of the National Comprehensive Cancer Network (2021) Vol. 20, Iss. 1, pp. 29-36
Open Access | Times Cited: 36
Engineered hydrogels for brain tumor culture and therapy
Jai Thakor, Samad Ahadian, A. Niakan, et al.
Bio-Design and Manufacturing (2020) Vol. 3, Iss. 3, pp. 203-226
Open Access | Times Cited: 38
Jai Thakor, Samad Ahadian, A. Niakan, et al.
Bio-Design and Manufacturing (2020) Vol. 3, Iss. 3, pp. 203-226
Open Access | Times Cited: 38
Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study
Hyehyun Jeong, J Y Shin, Jae Ho Jeong, et al.
ESMO Open (2021) Vol. 6, Iss. 3, pp. 100119-100119
Open Access | Times Cited: 29
Hyehyun Jeong, J Y Shin, Jae Ho Jeong, et al.
ESMO Open (2021) Vol. 6, Iss. 3, pp. 100119-100119
Open Access | Times Cited: 29
Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours
George Papaxoinis, Zoe Kordatou, Lynne McCallum, et al.
Neuroendocrinology (2019) Vol. 110, Iss. 5, pp. 413-421
Closed Access | Times Cited: 31
George Papaxoinis, Zoe Kordatou, Lynne McCallum, et al.
Neuroendocrinology (2019) Vol. 110, Iss. 5, pp. 413-421
Closed Access | Times Cited: 31
Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A “Real-World” Data Analysis
Alberto Bongiovanni, Chiara Liverani, Flavia Foca, et al.
Neuroendocrinology (2020) Vol. 111, Iss. 9, pp. 895-906
Closed Access | Times Cited: 31
Alberto Bongiovanni, Chiara Liverani, Flavia Foca, et al.
Neuroendocrinology (2020) Vol. 111, Iss. 9, pp. 895-906
Closed Access | Times Cited: 31
Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs): A Systematic Review and Pooled Analysis
Giulia Arrivi, Monica Verrico, Michela Roberto, et al.
Cancer Management and Research (2022) Vol. Volume 14, pp. 3507-3523
Open Access | Times Cited: 17
Giulia Arrivi, Monica Verrico, Michela Roberto, et al.
Cancer Management and Research (2022) Vol. Volume 14, pp. 3507-3523
Open Access | Times Cited: 17
A Ki-67 Index to Predict Treatment Response to the Capecitabine/Temozolomide Regimen in Neuroendocrine Neoplasms: A Retrospective Multicenter Study
Wei Wang, Yu Zhang, Ying Peng, et al.
Neuroendocrinology (2020) Vol. 111, Iss. 8, pp. 752-763
Closed Access | Times Cited: 26
Wei Wang, Yu Zhang, Ying Peng, et al.
Neuroendocrinology (2020) Vol. 111, Iss. 8, pp. 752-763
Closed Access | Times Cited: 26
Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide
Daniel Bengtsson, Henrik Daa Schrøder, Katarina Berinder, et al.
Endocrine (2018) Vol. 62, Iss. 3, pp. 737-739
Closed Access | Times Cited: 23
Daniel Bengtsson, Henrik Daa Schrøder, Katarina Berinder, et al.
Endocrine (2018) Vol. 62, Iss. 3, pp. 737-739
Closed Access | Times Cited: 23
Critical appraisal of MGMT in digestive NET treated with alkylating agents
Louis de Mestier, Anne Couvelard, Anela Blažević, et al.
Endocrine Related Cancer (2020) Vol. 27, Iss. 10, pp. R391-R405
Open Access | Times Cited: 20
Louis de Mestier, Anne Couvelard, Anela Blažević, et al.
Endocrine Related Cancer (2020) Vol. 27, Iss. 10, pp. R391-R405
Open Access | Times Cited: 20
Association between MGMT status and response to alkylating agents in patients with neuroendocrine neoplasms: a systematic review and meta-analysis
Zhirong Qi, Huangying Tan
Bioscience Reports (2020) Vol. 40, Iss. 3
Open Access | Times Cited: 19
Zhirong Qi, Huangying Tan
Bioscience Reports (2020) Vol. 40, Iss. 3
Open Access | Times Cited: 19
Challenges and future perspectives for the use of temozolomide in the treatment of SCLC
Elisa Andrini, Gianluca Ricco, Arianna Zappi, et al.
Cancer Treatment Reviews (2024) Vol. 129, pp. 102798-102798
Closed Access | Times Cited: 2
Elisa Andrini, Gianluca Ricco, Arianna Zappi, et al.
Cancer Treatment Reviews (2024) Vol. 129, pp. 102798-102798
Closed Access | Times Cited: 2
Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET
Susumu Hijioka, Keiichiro Sakuma, Masahiro Aoki, et al.
Cancer Chemotherapy and Pharmacology (2018) Vol. 83, Iss. 1, pp. 43-52
Closed Access | Times Cited: 19
Susumu Hijioka, Keiichiro Sakuma, Masahiro Aoki, et al.
Cancer Chemotherapy and Pharmacology (2018) Vol. 83, Iss. 1, pp. 43-52
Closed Access | Times Cited: 19
Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma
Noritoshi Kobayashi, Yuma Takeda, Naoki Okubo, et al.
Cancer Science (2021) Vol. 112, Iss. 5, pp. 1936-1942
Open Access | Times Cited: 15
Noritoshi Kobayashi, Yuma Takeda, Naoki Okubo, et al.
Cancer Science (2021) Vol. 112, Iss. 5, pp. 1936-1942
Open Access | Times Cited: 15
Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies
Lingaku Lee, Irene Ramos-Álvarez, Robert T. Jensen
Cancers (2022) Vol. 14, Iss. 5, pp. 1250-1250
Open Access | Times Cited: 11
Lingaku Lee, Irene Ramos-Álvarez, Robert T. Jensen
Cancers (2022) Vol. 14, Iss. 5, pp. 1250-1250
Open Access | Times Cited: 11
Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis
Francesca Spada, Patrick Maisonneuve, Caterina Fumagalli, et al.
Endocrine (2020) Vol. 72, Iss. 1, pp. 268-278
Closed Access | Times Cited: 16
Francesca Spada, Patrick Maisonneuve, Caterina Fumagalli, et al.
Endocrine (2020) Vol. 72, Iss. 1, pp. 268-278
Closed Access | Times Cited: 16
